Clinical Observation of Zhuang Medicine Yangxue Xiaozheng Decoction in Treating the Combined Endometriosis of Dampness and Blood Stasis in Guangxi

Objective:To explore the clinical effects of Zhuang Medicine Yangxue Xiaozheng Decoction in treating the combined Ems of dampness and blood stasis in Guangxi;Methods:100 patients with endometriosis treated in Lili Clinic of Famous Doctor,Guangxi International Zhuang Medicine Hospital from Mach 2016 to May 2017 were chosen as the research object.According to the random grouping method,patients were randomly divided into the treatment group(The Zhuang Medicine Yangxue Xiaozheng Decoction(ZYF)Group)and the control group(Chinese patent medicine SanJieZhenTongJiaoNang(SJZT)group with 50 cases in each group.After treatment,the TCM syndrome score,changes in pelvic mass size,hepatocyte growth factor(HGP)levels,and clinical effects before and after treatment were evaluated.Results:After two courses of treatment,the total effective rate of patients in the ZYF group was 88%,which were significantly better than 70%of the SJZT group.The difference was statistically significant(P<0.05).Conclusion:With a significant effect on patients with the combined Ems of dampness and blood stasis in Guangxi,Zhuang Medicine Yangxue Xiaozheng Decoction can improve the uterine cavity mass and reduce serum HGP level.

Efficacy of Modified Qufeng Runmian Powder(加减祛风润面散)on Acne Vulgaris with Syndromes of Dampness and Blood Stasis:A Multicenter,Randomized,Double-Blind,Placebo-Controlled Clinical Trial

Objective:To evaluate the efficacy and safety of a Chinese medicine(CM)Modified Qufeng Runmian Powder(加减祛风润面散,MQFRMP)for the treatment of acne vulgaris with CM syndromes of dampness and blood stasis.Methods:In this multicenter,randomized,double-blind,placebo-controlled clinical trial,220 acne vulgaris patients with CM syndrome of dampness and blood stasis were included and randomly assigned using a central area group random design to receive either MQFRMP or the placebo,with 110 cases in each group.MQFRMP or a placebo at 145 g/bag were administered once daily for 4 weeks,respectively.The primary index of efficacy was the effective rate according to the acne severity score(ASS).The secondary indices of efficacy included the changes in the dermatology life quality index(DLQI)score,VISIA scores(spots,pores,brown spots,porphyrins and red areas)and skin assessment(skin p H,sebum amount and hydration)according to a SOFT skin multianalyzer.Results:(1)Follow-up:a total of 204 patients completed the follow-up,with 103 in the treatment group and 101 in the control group.(2)Effective rate:the total effective rate of the treatment group was significantly higher than the control group[83.5%(86/103)vs.31.7%(32/101),P<0.01)]with 95%confidence interval of 39.3%–66.4%.(3)DLQI:DLQI scores were significantly decreased the treatment and control groups(both P<0.01),but the treatment group was more obvious than the placebo group(P<0.01).(4)VISIA scores:the scores of spots,brown spots and red areas in the treatment group decreased compared with baseline(P<0.05).In the control group,the scores of brown spots and pores decreased compared with baseline(P<0.05).The improvement was more obvious in the treatment group than in the control group for all items(P<0.05).(5)Skin assessment:the p H and sebum score in the both groups decreased drastically compared with the baseline(all P<0.01),however,the improvement was more obvious in the treatment group than in the control group(P<0.01).The hydration amount in the two groups showed no statistically significant difference compared with the baseline(both P>0.05).(6)Safety:two cases of mild drug allergy were observed in the treatment group.Conclusion:MQFRMP was effective and safe for the treatment of acne vulgaris with syndromes of dampness and blood stasis.(No.ChiCTR1900020479).